# Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

> **NCT00098839** · PHASE1,PHASE2 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 134 (actual)

## Conditions studied

- Recurrent Childhood Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** L-asparaginase
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** therapeutic hydrocortisone
- **DRUG:** vincristine sulfate
- **BIOLOGICAL:** epratuzumab
- **DRUG:** cytarabine
- **DRUG:** prednisone
- **DRUG:** pegaspargase
- **DRUG:** dexrazoxane hydrochloride
- **DRUG:** methotrexate
- **DRUG:** etoposide
- **DRUG:** cyclophosphamide
- **DRUG:** leucovorin calcium
- **BIOLOGICAL:** filgrastim

## Key facts

- **NCT ID:** NCT00098839
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2017-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00098839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00098839, "Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00098839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*